Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
ATHE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $4.71
Previous CloseN/A
Volume131.33K
Average Volume (3M)66.91K
Market Cap
$26.88M
Enterprise Value$2.03M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Feb 27, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding8,867,386
10 Day Avg. Volume28,027
30 Day Avg. Volume66,914
Standard Deviation0.28
R-Squared0.02
Alpha0.00490
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside88.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Alterity Therapeutics News
PremiumCompany Announcements
Alterity Therapeutics Expands ASX Quoted Securities---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAlterity Therapeutics reported positive clinical results for its Phase 2 trial of ATH434 in Multiple System Atrophy, including 48% slowing of clinical progression at the 50 mg dose level.
Regulatory SupportATH434 has orphan drug designation for MSA in both the US and EU, enhancing its potential marketability and regulatory support.
Therapeutic InnovationATH434 is a novel approach to address iron-induced α-synuclein aggregation by redistributing iron, offering a safer, potentially more effective therapeutic method.
Bears Say
Market SizeAlterity intends to engage the FDA to discuss next steps in the development of ATH434 in MSA, a disease with a small patient population but few treatment options.
Revenue RiskThe trial outcome has led to a reduction in revenue risk adjustment, raising the 12-month price target for the stock.
Stock RecommendationThe recommendation on ATHE shares is being lowered to Hold as these shares have exceeded the $4 price target.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.36% Other Institutional Investors
99.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $1.00 and its highest was $4.71 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $26.88M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 27, 2025 which is in 20 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 28, 2024. The company reported -$0.515 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.408.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate is -0.14.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 8,867,386 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.515 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
---
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (88.24% Upside)
$8.00 (88.24% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.55%
12-Months-Change
Fundamentals
Return on Equity
-138.60%
Trailing 12-Months
Asset Growth
-29.40%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
---
ATHE Stock 12 Month Forecast
Average Price Target
$8.00
▲(88.24% Upside)
Technical Analysis
Best Analysts Covering ATHE
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+40.00%
reiterated a buy rating 7 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +40.00% per trade.
---